Sterling Pharma Solutions
Keira Burns is a skilled professional in the field of biochemistry and vaccines, currently serving as a Process Development Scientist at Sterling Pharma Solutions since November 2023. Prior experience includes roles as Biochemistry Critical Raw Materials Supervisor and Manufacturing Scientist at Siemens Healthineers between April 2022 and November 2023. Keira's academic background features a PhD focused on Vaccines and Immunology from the London School of Hygiene and Tropical Medicine, earned in 2022, alongside a BSc in Molecular and Cellular Biology from the University of Bath completed in 2018. Notable research experience includes a joint PhD project at the National Institute for Biological Standards and Control investigating glycoconjugate vaccines, as well as placements at Public Health England and Quadram Institute, where Keira gained hands-on laboratory experience in vaccine development and immunological assays.
This person is not in any teams
This person is not in any offices
Sterling Pharma Solutions
1 followers
Sterling Pharma Solutions has over 50 years' experience serving the global pharmaceutical industry. Our facilities are located in Cramlington and Newcastle Biosphere, UK; Deeside, Wales; Cork, Ireland, as well as North Carolina and Wisconsin in the US. Our state-of-the-art facilities, proprietary technologies and experienced people are among the best in the industry. We have a proven track record in the supply of chemistry and analytical services across the entire product lifecycle, from grams to tonnes, from pre-clinical to commercial supply. Our world-class safety and quality standards are globally recognised and demonstrated through successful MHRA and FDA inspections and CIA Gold Awards for Safety the last three consecutive years. We pride ourselves on our customer focus and service approach, offering flexible, tailored solutions to our customers. In addition, our North Carolina and Newcastle Biosphere facilities offer expert chemistry solutions for small volume batches or products in the early stages of clinical trials. Our Deeside, Wales facility provide bioconjugation development services and specialised in antibody drug conjugation (ADC) research and development. Find out more: www.sterlingpharmasolutions.com/sterling-facilities